---
title: "Lonimecgene renparvovec (TSHA-102): Rett syndrome"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome. Clinical evidence covers REVEAL pivotal, ASPIRE, and REVEAL part A. 482 evidence topics quoted from 199 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102): Rett syndrome

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Lonimecgene renparvovec

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Rett syndrome

<a id="topic-1.1.1-1"></a>

##### Summary: definition and genetics

- Definition: Rett syndrome is a progressive neurodevelopmental disorder that affects mainly females. In classic Rett syndrome, psychomotor development appears normal for the first 6 to 18 months of life and is followed by regression of spoken language and purposeful hand use; this regression, together with hand stereotypies and impaired walking, forms the four principal diagnostic criteria. After regression, skills stabilize, and some individuals partly regain them.
- Genetics: pathogenic MECP2 variants are found in 95% to 97% of individuals with typical Rett syndrome and in 50% to 70% of those with atypical presentations, and 3% to 5% of individuals who meet strict clinical criteria have no identified MECP2 variant, so the diagnosis remains clinical. Variants in CDKL5 have been found in the early seizure variant.
- Inheritance: MECP2 disorders are X-linked, and more than 99% are simplex cases arising from a de novo variant or possibly from parental germline mosaicism. In 27 families with sporadic Rett syndrome, the de novo variant was of paternal origin in 26 of 27 cases (P<.001), which the authors propose as the most probable cause of the female predominance.
- Males: severe neonatal-onset encephalopathy is the most common phenotype in males with an MECP2 variant, and death often occurs before 2 years of age. Among 30 males with MECP2 variants in the Natural History Study databases, the phenotype ranged from severe neonatal encephalopathy to cognitive impairment.

Source: [Gold et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39511247/); [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/); [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/); [Trappe et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1226090/); [Neul et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6488031/)

<a id="topic-1.1.1-2"></a>

##### Summary: incidence and prevalence

- Global estimates: a meta-analysis of 10 studies, all in females, with 9.57 million women and 673 cases, estimated a pooled prevalence of 7.1 per 100,000 females (95% CI 4.8 to 10.5), with study estimates ranging from 0.0 to 38.3 per 100,000 females; no included study had participants with Rett syndrome older than 35 years. Other sources give a worldwide prevalence of 1:10,000 to 1:23,000 female births and approximately 1 in 10,000 live female births. The Canadian trofinetide reimbursement review gives 1 in 10,000 females aged 12 years and younger and a worldwide prevalence of 1 in 20,000 to 1 in 40,000.
- Australia: among 349 females born from 1976 to 2006, the birth prevalence was 9.37 per 100,000 female births (95% CI 8.41 to 10.41). Point prevalence in June 2009 was 8.6 per 100,000 females aged 5 to 18 years (95% CI 7.4 to 10.1) and 5.8 per 100,000 females aged 19 to 32 years (95% CI 4.8 to 6.9).
- Cumulative incidence: another analysis reports a cumulative incidence of 1.09 per 10,000 females by 12 years of age.
- Europe: in France, the incidence of Rett syndrome with an MECP2 variant was 0.43 to 0.71 per 10,000 females, described as a minimum estimate, and the prevalence was 0.558 per 10,000 females aged 4 to 15 years. In Serbia, 102 girls were diagnosed from 1981 to 2012, an incidence of 0.586 per 10,000 female live births, and the prevalence in females younger than 19 years was 1:8,439.
- IQVIA claims: in the IQVIA Dx and LRx databases, annual prevalence from November 1, 2016 to October 31, 2019 was 0.30 to 0.32 per 10,000 enrollees overall and 0.45 to 0.52 per 10,000 among female enrollees. Annual incidence among female enrollees was 0.43 and 0.31 per 10,000 in 2018 and 2019.
- Canada: Ontario recorded 57 incident cases from September 2017 to August 2023 and 257 prevalent cases from April 2002 to August 2023. The trofinetide manufacturer estimated 600 to 900 cases in Canada, extrapolated from United States data.
- Company estimates: Acadia Pharmaceuticals estimates from 2024 claims that approximately 6,000 people in the United States are diagnosed, with a prevalent population of 6,000 to 9,000, and 9,000 to 12,000 in the European Union. Taysha Gene Therapies estimates 6,000 to 9,000 patients in the United States and an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 variant in the United States, the European Union, and the United Kingdom.

Source: [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/); [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/); [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/); [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1); [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/); [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/); [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/); [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/); [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/); [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/); [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-1.1.1-3"></a>

##### Summary: natural history and survival

- Regression: regression began between 12 and 30 months of age in more than 80% of individuals (36.2% at 12 to 18 months and 46.1% at 18 to 30 months), and another cohort reports a median of 18 months. The median age of skill loss was 3 years or younger for 46 of 51 developmental skills (90%). Regain of lost skills occurred mainly before 6 years of age, and after that age the gain of new skills or regain of lost skills was infrequent.
- Later life: in a cohort of 30 women, severity increased little over time, and some features, including epilepsy, agitation, sleep, and hand stereotypies, improved with age.
- Survival: in one cohort, 51 of 1189 participants died during 9 years of follow-up, survival exceeded 70% at 45 years for classic and atypical Rett syndrome, and at least 95% of the classic population was estimated to survive to age 20, 80% to age 35, and over 70% to age 50. In the Australian Rett Syndrome Database (n = 396), the conditional probability of survival was 77.6% at 20 years, 71.5% at 25 years, and 59.8% at 37 years. In a further analysis, 305 deaths (15.8%) had occurred as of January 1, 2006, and mortality was higher in typical than in atypical Rett syndrome (p<.0001). In a further cohort, median age at death was 13 years 4.8 months, and survival to 25 years was 21% against 71% in the Australian cohort (p<0.001).
- Causes of death: among 57 deceased females with a recorded cause, lower respiratory tract infection accounted for 36.8% (21/57), aspiration or asphyxiation for 31.6% (18/57), respiratory failure for 14.0% (8/57), and seizure-related illness for 5.3% (3/57). Cardiorespiratory dysfunction may account for 26% to 47% of sudden, unexpected deaths.
- Risk factors: in classic Rett syndrome, ambulation status, frequent seizures, frequent hospitalizations and illness, microcephaly, and low weight were independently associated with mortality, and 54% (19/35) of those who died weighed less than the 25th percentile on Rett-specific charts against 22% of survivors (p < .001).

Source: [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/); [Cutri-French et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8882337/); [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/); [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/); [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/); [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/); [Kirby et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2794941/); [Freilinger et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20573179/); [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/)

<a id="topic-1.1.1-4"></a>

##### Summary: symptom domains and long-term morbidity

- Range across studies: a systematic review of 148 studies from 24 countries, with participants aged 7 months to 37 years, reports prevalence ranges of 15.0% to 91.0% for epilepsy, 8.9% to 100% for scoliosis, 16.4% to 82.8% for constipation, 15.8% to 100.0% for gastroesophageal reflux, 68.0% to 100.0% for intellectual disability, 18.2% to 95.5% for dystonia, 23.5% to 76.7% for dysphagia and chewing problems, and 39.2% to 92.9% for drooling.
- Motor and communication: nearly 100% of individuals had abnormal hand function, more than 70% had delayed walking, and nearly 34% never acquired walking. Hand stereotypies were reported in all 922 participants with classic Rett syndrome. Nearly all participants had delayed language development and 90% had abnormal nonverbal communication; 88.6% lost previously gained words with meaning.
- Seizures and autonomic function: the point prevalence of active seizures was 30% to 44% and the estimated cumulative lifetime prevalence of epilepsy approached 90%. Breathing dysfunction affected nearly 100% of those with classic or atypical severe Rett syndrome over the lifespan and 60% to 70% of those with atypical mild Rett syndrome. Of 613 participants with electrocardiogram data, 18% had a borderline and 10% an abnormal QTc interval.
- Gastrointestinal, sleep, and behavior: gastrointestinal and orthopaedic comorbidities are each reported in over 80% of individuals in one publication, and gastrointestinal manifestations that led to a healthcare encounter were recorded in 43.0% of 5940 patients. Sleep problems were identified in over 80% of cases, and 77.5% of participants had at least occasional anxious or nervous behavior. Mean head circumference fell below the normative population at 1 month, weight at 6 months, and length at 17 months.
- Orthopaedic and bone: a meta-analysis estimates that approximately two in three girls develop scoliosis, one in two foot deformities, and one in three hip displacement. Among 913 females with classic Rett syndrome, 251 (27%) had severe scoliosis and 168 (18%) had surgical correction, at a median age of 12 years. Fracture incidence in an Australian population was 43.3 per 1000 person years, nearly four times that of the general population.
- Adulthood: in a cohort with a median age of 25 years (range 18 to 54), 71% lived in the parental home, 18% walked independently and 43% with assistance, 86% had scoliosis (40% of them corrected surgically), 64% took antiepileptic medication, 83% had constipation, and 63% had sleep disturbance. Among 24 individuals aged 30 to 66 years followed for 6 to 12 years, gross motor scores declined. Of 26 women who walked after childhood regression, 2 (8%) lost walking in their 20s, and 9 (37.5%) of those still walking in their 40s lost it in their 40s or 50s.
- Respiratory complications: of 1,994 individuals in one analysis, 7.27% had aspiration, 9.48% lower respiratory tract infection, and 10.08% respiratory failure after the index date.

Source: [Rashid et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556918/); [Percy et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12380397/); [Stallworth et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6556084/); [Neul et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094048/); [Tarquinio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5278305/); [Tarquinio et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6026556/); [Tarquinio et al. (2015b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4609589/); [Fu et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7509967/); [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/); [Young et al. (2007)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2527512/); [Buchanan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9107202/); [Tarquinio et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3468773/); [Galán-Olleros et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39429113/); [Killian et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5461984/); [Jefferson et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4743907/); [Anderson et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4078387/); [Bisgaard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34296518/); [Hryniewiecka-Jaworska et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975466/); [Rajagopalan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12580911/)

<a id="topic-1.1.1-5"></a>

##### Summary: humanistic burden

- Quality of life of the affected individual: among more than 200 participants aged 5 to 18 years with classic Rett syndrome, every CHQ-PF50 domain score other than Behavior and Family Cohesion was significantly lower than the standard score for US girls. The 23 parents in another study rated their children's quality of life as reduced.
- Caregiver health: in one cohort, caregivers had a mean physical component score of 52.8 (9.7) and a mental component score reported as 44.5 (12.1) and, in the comparison with the general population, 44.6 (12.1); females aged 35 to 44 years in the US general population score 51.6 (8.6) and 47.8 (10.4). Among 37 UK caregivers in a multi-method study conducted from June to August 2025, the mean EQ-5D-5L score was 0.62 (SD=0.25), 49% reported moderate to severe anxiety or depression, 38% reported moderate to severe pain or discomfort, and the mean CarerQoL-7D utility was 60.76 (SD=18.11). In another study, 60% of parents reported stress in the clinical range on at least one Parenting Stress Index subscale.
- Symptoms with the greatest impact: in an international survey of 756 caregivers, core impairments were present in 70% to 98% of affected individuals, and problem frequency ranged from about 35% for hyperventilation to 99% for impaired self-care. In a survey of 323 caregivers in the USA, the UK, Canada, and Israel funded by Taysha Gene Therapies, loss of speech (81%, n = 261), loss of purposeful hand use (80%, n = 259), and loss of independent walking (61%, n = 198) were most often rated as having a severe impact on quality of life, and 76% (n = 245) reported at least 1 new or newly challenging symptom in the previous 2 years.
- Daily activities: in diaries from 60 caregivers in eight countries, symptoms affected 59% of activities for children, 61% for adolescents, and 38% for adults, and caregivers of adults spent an average of 41 hours per week on emotional support and 20 hours on feeding.

Source: [Lane et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3233210/); [Rozensztrauch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8111277/); [Killian et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4899118/); [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study); [Byiers et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3992319/); [Kaufmann et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11323357/); [Ben-Zeev et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13615242/); [Pulles et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13721293/)

<a id="topic-1.1.1-6"></a>

##### Summary: economic burden

- IQVIA claims: among 5,940 female patients (3,078 pediatric and 2,862 adult) in the IQVIA Dx and LRx databases from November 1, 2016 to October 31, 2019, with a mean observation period of 2.04 years, mean all-cause healthcare costs were $40,326 per patient per year in 2021 US dollars, $45,718 for pediatric and $34,548 for adult patients. Costs related to Rett syndrome made up 45% of all-cause costs. All-cause resource use was 44.43 visits per patient per year, led by home or hospice care (16.31 visits). The authors note that pre-adjudicated medical claims may overestimate costs. Managing gastrointestinal manifestations cost a mean of $4473 per patient per year.
- Other settings: in the Australian Rett Syndrome Database, mean healthcare costs were AUD 21,158 per patient per year (USD 25,691 as of December 2022), ranging from AUD 238 to AUD 85,776. Among 246 cases in Ontario, 76.8% had an emergency department visit and 54.5% an inpatient hospitalization. In another cohort, 44.6% of individuals had a hospital or emergency room visit over a median of 4 years, and 13.7% had a gastrostomy tube placed.
- Surgery: in the Kids' Inpatient Database, a Rett syndrome diagnosis independently predicted higher odds of complications (odds ratio 1.98) and longer stay (odds ratio 1.18) for posterior spinal fusion admissions.
- Families: among 37 UK caregivers, caregiving averaged 98.9 hours per week, 14% worked full time, and 60% had stopped working.
- Diagnostic testing: Prices for MECP2 sequencing (CPT 81302) were $685 in one price list and $900 in another. The Canadian reimbursement review estimates approximately $1,307.45 per sample for MECP2 testing.
- Evidence base: a literature review found cost or resource use outcomes in 11 publications and no pharmacoeconomic models or comprehensive estimates of total economic burden.

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/); [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/); [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/); [May et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11282812/); [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/); [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study); [Nemours (2026)](https://www.nemours.org/content/dam/nemours/nemours-org/en/documents/molecular-diagnostic-lab-cpt-codes-and-billing.pdf); [Greenwood Genetic Center](https://ggc.org/tests/rett-syndrome-mecp2-sequencing/); [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1); [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

<a id="heading-1.1.2"></a>

#### 1.1.2 Lonimecgene renparvovec Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: REVEAL Part A pooled phase 1/2 efficacy at the May 2026 data cutoff

- Population and follow-up: REVEAL Part A pools two first-in-human, open-label phase 1/2 dose-escalation trials of a single lumbar intrathecal administration, one in females aged 12 years and older (NCT05606614 Part A, registered for ages 12 to under 22 years) and one in females aged 5 to 8 years (NCT06152237), each with 6 participants enrolled. As of the May 2026 data cutoff, 12 participants aged 6 to 21 years at dosing had received TSHA-102 (low dose of 5.7x10^14 total vector genomes, 4 participants; high dose of 1x10^15 total vector genomes, 8 participants), with baseline CGI-S scores of 4 to 6 and post-treatment follow-up of 12 to 30 months. Results at 6 and 12 months include all 12 participants, and results at 18 months or more include 7.
- Developmental milestones: the response rate, defined as the percentage of participants who gain or regain at least 1 of 28 developmental milestones assessed by multiple independent central raters through video evidence, was 83% (10 of 12) at 6 months, 100% (12 of 12) at 12 months, and 100% of 7 participants at 18 months or more. At 12 months or more, the poster reports 310 functional gains and improvements (about 26 per participant), comprising 31 developmental milestones and 279 additional skill gains or improvements, with 16 milestones in 6 pediatric participants and 15 in 6 adolescent or adult participants; milestone gains increased by 69% from 6 to 12 months. The additional skills comprised 53 MSEL-A skill gains, 128 ORCA skill gains, and 98 R-MBA improvements, with ORCA data for 8, MSEL-A data for 7, and R-MBA data for 12 participants.
- Clinician-rated scales: the mean R-MBA change from baseline was -11.0 at 6 months against -0.81 in the natural history comparison (P = 0.0011) and -10.3 at 12 months against -0.62 (P = 0.0002), and -11.0 at 18 months or more (P = 0.0046). All participants (100%) had a CGI-I score of 3 or less at multiple post-treatment assessments at each time point, and the proportion with CGI-S improvement was 25% at 6 months, 25% at 12 months, and 57% at 18 months or more.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237)

<a id="topic-1.1.2-2"></a>

##### Summary: dose comparison in REVEAL Part A

- The 2026 poster (May 2026 data cutoff) and the company's June 2026 program update presentation report an average score of -15.7 in the high-dose cohort and -7.8 in the low-dose cohort, which the presentation gives for 18 months or more after dosing. At the May 2026 data cutoff, treatment-related adverse events occurred in 5 high-dose participants (20 events) and 4 low-dose participants (17 events).
- The earlier 2025 poster reported, for the low-dose and high-dose cohorts respectively, a developmental milestone responder rate at 6 months of 75% and 83%, a mean R-MBA improvement of -9.8 and -12.2 at 6 months and -11.5 and -18.0 at 9 months or more, a mean CGI-I score of 2.3 and 2.0 at 6 months and 2.8 and 1.0 at 9 months or more, and CGI-S improvement at the latest visit in 25% and 33% of participants. The company Form 10-K gives the high-dose 6-month response as 83% (5 of 6 participants; May 2025 data cutoff).
- The high dose of 1x10^15 total vector genomes was carried into the pivotal trial and, scaled for brain volume, into ASPIRE.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-1.1.2-3"></a>

##### Summary: REVEAL Pivotal design and status

- Design: the REVEAL pivotal trial (Part B of NCT05606614) is a single-arm, open-label study of a single lumbar intrathecal administration of the high dose (1x10^15 total vector genomes) in females aged 6 to under 22 years with Rett syndrome due to an MECP2 loss-of-function mutation who are in the developmental plateau population, with each participant serving as their own control. Central raters assessing milestone gain or regain from videos are blinded to the timing of each video.
- Endpoints and analysis: the primary endpoint is the response rate, the percentage of participants who gain or regain at least 1 of 28 natural history defined developmental milestones across communication, fine motor, and gross motor domains. Key secondary endpoints are the average number of milestones gained or regained per participant, the R-MBA, and the CGI-I. The null hypothesis, derived from natural history data, is a response rate of 6.7% (1 of 15 participants aged 6 years or older), and a response rate of 33% (5 of 15) is the minimum threshold for success. The statistical analysis plan names a 12-month primary analysis, and the company reports FDA alignment on a potential BLA submission based on a 6-month interim analysis.
- Status: the first participant was dosed in December 2025, and dosing was completed in 17 participants against a planned 15. The interim analysis is expected after all 17 participants complete 6 months of follow-up, with topline data and FDA feedback on the BLA submission pathway expected in the first half of 2027. No efficacy results have been reported.

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-1.1.2-4"></a>

##### Summary: ASPIRE design and status

- ASPIRE (NCT07480564) is an open-label study of the safety, tolerability, and preliminary efficacy of a single intrathecal administration of TSHA-102 at 1x10^15 total vector genomes adjusted for brain volume, given by lumbar puncture, in females aged 2 to less than 4 years with typical Rett syndrome. The primary endpoint is the proportion of participants with any treatment-emergent adverse event and serious adverse event from baseline through week 25, followed by an extended observation period through 5 years.
- The study started on 2026-05-08, with estimated primary completion in 2031-06, and is registered as active, not recruiting. Enrollment was planned at 3 participants, and the company completed dosing in 4.
- The company reports written FDA alignment that the planned BLA will include at least 3 months of safety data from 3 participants aged 2 to under 4 years in ASPIRE, while efficacy data from REVEAL pivotal participants aged 6 to under 22 years are to represent children aged 2 to under 6 years. No ASPIRE-specific efficacy or safety results have been reported.

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm); [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-1.1.2-5"></a>

##### Summary: safety

- REVEAL Part A (May 2026 data cutoff, 12 participants): treatment-related treatment-emergent adverse events occurred in 9 participants (37 events), serious treatment-emergent adverse events unrelated to TSHA-102 in 7 participants (17 events), and no participant had a treatment-related serious adverse event or a dose-limiting toxicity. All treatment-related events were mild to moderate; the most common were elevated liver enzymes (4 participants, 33%), increased cerebrospinal fluid protein (3, 25%), and pyrexia (3, 25%). The 2025 poster reported that most liver enzyme elevations were below 2 times the upper limit of normal and that acute excursions above 5 times the upper limit of normal were less common, asymptomatic, and responsive to steroid treatment.
- Immunosuppression: immunoprophylaxis with oral prednisolone and sirolimus begins 7 days before dosing, with the prednisolone taper planned from week 17 to week 25 and the sirolimus taper from week 38 in the pediatric protocol design. In the company's 2024 first-cohort data presentation, 34 treatment-emergent adverse events had occurred as of 05/10/2024, 33 of them mild or moderate; the most common was vomiting (5 events), a known risk of sirolimus, and 8 nonserious events were related to immunosuppression (2 vomiting events, dermatitis acneiform, cystatin C increase, blisters, myopathy, chronic renal disease, and a second myopathy). One severe, grade 3 serious adverse event, a change in seizure presentation, was judged unrelated to TSHA-102.
- REVEAL Pivotal: the company reported no treatment-related serious adverse events or dose-limiting toxicities in the REVEAL pivotal trial as of the March 2026 data cutoff, and its announcement of completed pivotal dosing reported none as of the June 2026 data cutoff without naming the trials that statement covers. In July 2026, about 6 weeks after dosing, one participant had a treatment-related, moderate Grade 2 event of peripheral sensory neuropathy, which the company describes as an expected risk of AAV therapy; the event was classified as a serious adverse event because the participant was admitted overnight under the treating institution's protocol. The company reports that the participant was discharged the following day and had nearly returned to baseline over the following three months.
- Pooled across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4), the company reports no severe treatment-related serious adverse events or dose-limiting toxicities in 33 participants as of the November 2026 data cutoff, with all participants past the acute post-dosing safety monitoring period.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf); [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf); [Taysha Gene Therapies first-cohort data HCP presentation (2024)](https://tayshagtx.com/wp-content/uploads/First-cohort-Data-from-the-REVEAL-AdolescentAdult-and-Pediatric-Studies-of-TSHA-102-Gene-Therapy-for-Rett-Syndrome-1.pdf); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-1.1.2-6"></a>

##### Summary: limitations of the evidence

- Sample size: efficacy data come from 12 participants in REVEAL Part A, 4 at the low dose and 8 at the high dose, with 7 contributing results at 18 months or more. The pivotal trial dosed 17 participants and ASPIRE dosed 4, and neither has reported efficacy results.
- Design: all three trials are open label. The pivotal trial is single arm with each participant serving as their own control, and the 2026 poster describes REVEAL as using each participant as their own control. The pediatric Part A trial is registered with no masking, and in NCT05606614 only the central raters of milestone videos are masked, to the timing of each video. The R-MBA and CGI-I are clinician-assessed measures and ORCA is a caregiver report. The registered primary outcome of the Part A trials is the incidence of treatment-emergent adverse events and serious adverse events.
- External comparator: Part A R-MBA results are compared with natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA. The pivotal null response rate of 6.7% is derived from natural history data, in which first-time milestone gain after 6 years of age was below 3% across milestones and spontaneous first-time gain of a single milestone before 6 years of age was as high as 97%. The FDA draft guidance on small-population trials states that objectively measured endpoints that are not effort-dependent are critical for interpreting self-controlled or other non-blinded trials. A poster on the natural history analysis cites ethical and methodological concerns with sham controls and functional unblinding from required immunosuppression as obstacles to a controlled design.
- Source of data: the results come from company press releases, SEC filings, investor presentations, and congress posters. The 2025 poster states that its data reflected the electronic data capture system and were subject to change. Pivotal-trial safety is reported mostly as pooled statements across 33 participants, and efficacy in children aged 2 to under 6 years is to be extrapolated from older participants.

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Rossignol et al. (2025a)](https://tayshagtx.com/wp-content/uploads/REVEAL-AdolescentAdult-and-Pediatric-Clinical-Trial-Update-Safety-and-Efficacy-Data-on-TSHA-102-AAV9-Investigational-Gene-Therapy-in-Clinical-Evaluation-for-Rett-Syndrome.pdf); [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614); [ClinicalTrials.gov NCT06152237](https://clinicaltrials.gov/study/NCT06152237); [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf); [FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025)](https://www.fda.gov/media/188892/download); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Lonimecgene renparvovec

<a id="topic-1.1.3-1"></a>

##### Summary

No published economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of lonimecgene renparvovec (TSHA-102) was identified, and no price or pricing guidance has been announced. Taysha Gene Therapies has generated no revenue from commercial product sales, and access to TSHA-102 is currently limited to clinical trial participation, with no expanded access offered.

Taysha's annual report estimates an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 mutation in the United States, the European Union, and the United Kingdom, including 6,000 to 9,000 patients in the United States based on claims data and epidemiology data; the same report states that incidence and prevalence estimates rest on inexact assumptions and that the methodology is forward-looking and speculative. The third quarter 2026 results announcement repeats the 15,000 to 20,000 estimate.

Taysha's commercial preparations, as described in its own disclosures, include a commercial manufacturing and supply agreement with Catalent at an FDA-licensed gene therapy facility in Harmans, Maryland; a completed process performance qualification campaign for the commercial manufacturing process; $50.0 million in gross proceeds from its at-the-market equity offering, with proceeds intended to support a potential commercial inventory build in 2027; and the February 2026 appointment of a Senior Vice President, Market Access and Value, who previously worked on market access for Zolgensma at AveXis. The company describes TSHA-102 as a one-time intrathecal administration with potential to be performed in an outpatient setting, and cites the commercial launch and uptake of trofinetide (DAYBUE) as evidence of market demand. In its second quarter 2026 results announcement, Taysha reported completed payer research in which TSHA-102 was viewed as a high-value therapy, and stated that efficacy, safety, and durability are expected to drive coverage and reimbursement, with durable functional benefit as the key value determinant. Its annual report states that the reimbursement structure of other companies' approved gene therapies could affect the anticipated reimbursement structure of its own products.

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/); [Taysha Gene Therapies Catalent commercial manufacturing announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-and-catalent-expand-strategic-partnership); [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm); [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-1.1.3-2"></a>

##### Summary: eligible population and cost of care for Rett syndrome

Acadia Pharmaceuticals estimates, based on 2024 claims data, that approximately 6,000 people are diagnosed with Rett syndrome in the United States, within a prevalent population of 6,000 to 9,000, and a prevalent population of 9,000 to 12,000 in the European Union. In IQVIA medical and prescription claims from November 1, 2016, to October 31, 2019, the annual prevalence of a Rett syndrome diagnosis was 0.30 to 0.32 per 10,000 enrollees overall and 0.45 to 0.52 per 10,000 among females. A meta-analysis of 10 studies in females, with 9.57 million women and 673 cases, estimated a pooled prevalence of 7.1 per 100,000 females (95% CI: 4.8, 10.5).

In the same IQVIA claims analysis, 5,940 female patients (3,078 pediatric, 2,862 adult; mean observation period 2.04 years) had mean all-cause healthcare costs of $40,326 per patient per year in 2021 US dollars, comprising $34,772 (86%) in pre-adjudicated medical costs and $5,554 (14%) in adjudicated pharmacy costs. Rett syndrome-related costs comprised 45% of all-cause costs ($14,643 medical and $3,428 pharmacy per patient per year). The largest medical cost components were home or hospice care visits ($12,054), therapeutic services ($7,071), outpatient visits ($6,791), and inpatient visits ($6,088). Mean all-cause costs were $45,718 in pediatric and $34,548 in adult patients. The authors state that pre-adjudicated claims may overestimate costs and that institutional claims are captured less completely than outpatient claims. A related claims analysis estimated mean medical costs of managing gastrointestinal manifestations at $4473 per patient per year ($5530 pediatric, $3341 adult). In the Australian Rett Syndrome Database, mean healthcare costs were AUD 21,158 per patient per year (USD 25,691 as of December 2022), ranging from AUD 238 to AUD 85,776.

In a UK caregiver study, average weekly caregiving time was 98.9 hours, 14% of caregivers worked full time, and 60% had stopped working completely. Genetic testing for MECP2 is listed under procedure codes 81302 (full sequence analysis), 81303 (known familial variant), and 81304 (duplication or deletion variants), and one payer policy states that it may be considered medically necessary to establish a genetic diagnosis when a definitive diagnosis cannot be made without genetic testing. A systematic literature review identified 11 publications reporting cost or healthcare resource use outcomes and stated that cost data in the literature were limited.

Source: [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm); [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/); [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/); [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/); [Pimprikar et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-2-4/the-impact-of-caring-for-their-children-with-rett-syndrome-a-multi-method-study); [Blue Shield of California (2023)](https://blueshieldca.com/content/dam/bsca/en/provider/docs/medical-policies/Genetic-Test-Rett-Syndrome.pdf); [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

<a id="topic-1.1.3-3"></a>

##### Summary: trofinetide as the comparator benchmark

Acadia stated a list price for trofinetide (DAYBUE) of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year. Acadia reported net product sales of DAYBUE of $177.2 million in 2023, $348.4 million in 2024, and $391.4 million in 2025, attributing the 2025 increase to growth in unit sales and a higher average net selling price. In a real-world analysis, 766 of 2,950 eligible individuals (26.0%) initiated trofinetide during the early post-approval period.

Canada's Drug Agency (CDA-AMC) appraised the sponsor's cost-effectiveness and budget impact analyses for trofinetide, and no other published cost-effectiveness or budget impact analysis of a Rett syndrome therapy was identified; amounts below are those reported in that review. The sponsor's Markov cost-utility model compared trofinetide plus best supportive care with best supportive care alone, using 4 health states defined by Rett Syndrome Behaviour Questionnaire (RSBQ) score plus death, a lifetime horizon of 79.1 years, and a 1.5% annual discount rate. Modeled annual drug cost was $455,251 to $1,113,127 (up to 40 kg). Health state utilities ranged from 0.6409 (mild to moderate) to 0.2160 (very severe). The model produced an incremental cost-effectiveness ratio of $5,864,321 per quality-adjusted life-year (QALY) gained (incremental costs $3,386,675; incremental QALYs 0.578), with a 0% probability of cost-effectiveness at $50,000 and $100,000 per QALY gained; a price reduction of more than 98% would be required to meet the $100,000 threshold. Of the incremental QALYs, 93% accrued beyond the trial observation period.

The sponsor's budget impact analysis took the perspective of the pan-Canadian drug plans over 2025 to 2027 and assumed 95, 21, and 22 patients would start publicly reimbursed trofinetide in years 1, 2, and 3. The CDA-AMC reanalysis estimated a 3-year incremental budgetary cost of $166,461,725 (year 1: $53,775,386; year 2: $53,706,466; year 3: $58,979,873), with scenario analyses reaching up to $333 million. CDA-AMC cites approximately 600 to 900 patients with Rett syndrome in Canada. CDA-AMC recommended that trofinetide not be reimbursed by public drug plans.

Source: [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome); [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm); [Rashid et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13264036/); [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1); [CDA-AMC trofinetide reimbursement recommendation (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829/2636?inline=1)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Rett syndrome is a progressive neurodevelopmental disorder that affects mainly females. Pathogenic MECP2 variants are found in 95% to 97% of individuals with typical Rett syndrome, and a meta-analysis of 10 studies estimated a pooled prevalence of 7.1 per 100,000 females (95% CI 4.8 to 10.5); Taysha Gene Therapies estimates 6,000 to 9,000 patients in the United States. Trofinetide is indicated in the United States for Rett syndrome in adults and pediatric patients 2 years of age and older, and its mechanism of action in Rett syndrome is unknown. In its 12-week randomized trial, the difference from placebo in RSBQ total score change was -3.2 (95% CI -5.7 to -0.6), which the European Medicines Agency described as small, and diarrhea occurred in 82% of participants receiving trofinetide against 20% receiving placebo. The other available treatments address individual comorbidities.

TSHA-102 is investigational, it is not authorised in the European Community, and Taysha has generated no revenue from the commercial sale of approved products. The FDA has granted it Breakthrough Therapy designation (September 2025), Regenerative Medicine Advanced Therapy designation (April 2024), Fast Track designation, and orphan drug and rare pediatric disease designations; it also holds orphan drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the UK Medicines and Healthcare products Regulatory Agency (February 2024). The company reports FDA alignment on a BLA pathway that includes the potential to submit for approval based on a 6-month interim analysis of the REVEAL pivotal trial, with data intended to support labeling for patients aged 2 years and older. Topline interim data and FDA feedback on the BLA submission pathway are expected in the first half of 2027, and FDA feedback following a chemistry, manufacturing and controls Type B meeting is expected in the first quarter of 2027.

In REVEAL Part A, open-label phase 1/2 trials of a single lumbar intrathecal administration, 12 females aged 6 to 21 years at dosing were treated (4 at the low dose and 8 at the high dose), with post-treatment follow-up of 12 to 30 months as of the May 2026 data cutoff. The response rate for gain or regain of at least 1 of 28 developmental milestones was 83% (10 of 12) at 6 months and 100% (12 of 12) at 12 months. The mean R-MBA change at 12 months was -10.3 against -0.62 in a natural history comparison (P = 0.0002), and 25% of participants had CGI-S improvement at 12 months. These results come from 12 participants, are compared with external natural history data, and are reported in company posters and filings; in natural history data, spontaneous first-time gain of a single milestone before 6 years of age was as high as 97%.

The REVEAL pivotal trial is a single-arm, open-label study of the high dose (1x10^15 total vector genomes) in females aged 6 to under 22 years, with each participant serving as their own control, and dosing was completed in 17 participants. Its primary endpoint is the milestone response rate, with a null hypothesis of 6.7% derived from natural history data and a minimum threshold for success of 33% (5 of 15 participants). The interim analysis is expected after all 17 participants complete 6 months of post-treatment follow-up. ASPIRE treated 4 participants aged 2 to under 4 years, and efficacy in children aged 2 to under 6 years is to be extrapolated from REVEAL pivotal data. No efficacy results from either trial have been reported.

In REVEAL Part A, 9 of 12 participants had treatment-related treatment-emergent adverse events (37 events), all mild to moderate, most often elevated liver enzymes (4 participants, 33%), increased cerebrospinal fluid protein (3, 25%), and pyrexia (3, 25%); 7 participants had serious events unrelated to TSHA-102, and none had a treatment-related serious adverse event or dose-limiting toxicity. In the pivotal trial, one participant had a treatment-related, moderate Grade 2 event of peripheral sensory neuropathy about 6 weeks after dosing, classified as a serious adverse event because of an overnight admission under the treating institution's protocol. The company reports no severe treatment-related serious adverse events or dose-limiting toxicities in 33 participants across the three trials as of the November 2026 data cutoff. In the pediatric protocol design, immunoprophylaxis with oral prednisolone and sirolimus begins 7 days before dosing.

No published economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of TSHA-102 and no price for it were identified, and access is currently available only through clinical trial participation. In IQVIA claims, 5,940 female patients with Rett syndrome had mean all-cause healthcare costs of $40,326 per patient per year in 2021 US dollars. Acadia stated a list price for trofinetide of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year; the sponsor model reviewed by Canada's Drug Agency produced an incremental cost-effectiveness ratio of $5,864,321 per QALY gained, and the agency recommended that trofinetide not be reimbursed by public drug plans. Taysha reports payer research in which TSHA-102 was viewed as a high-value therapy, with durable functional benefit as the key value determinant.

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/); [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/); [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Acadia DAYBUE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217026s008lbl.pdf); [EMA Daybu EPAR (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/daybu); [Fu et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7488790/); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [EMA paediatric investigation plan decision (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000232894-ema-decision-14-april-2025-agreement-paediatric-investigation-plan-granting-deferral-adeno-associated-viral-vector-serotype-9-containing-human-mecp2-gene_en.pdf-0); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm); [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf); [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/); [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564); [Devidze et al. (2023)](https://tayshagtx.com/wp-content/uploads/Design-of-the-REVEAL-Pediatric-study-of-TSHA-102-gene-therapy-for-Rett-Syndrome.pdf); [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/); [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome); [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1); [CDA-AMC trofinetide reimbursement recommendation (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829/2636?inline=1); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

## Related pages
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
